TWI623528B - 金屬酶抑制劑化合物、抑制金屬酶活性之方法、組合物、治療或預防植物疾病或病症之方法及其用途 - Google Patents

金屬酶抑制劑化合物、抑制金屬酶活性之方法、組合物、治療或預防植物疾病或病症之方法及其用途 Download PDF

Info

Publication number
TWI623528B
TWI623528B TW105144241A TW105144241A TWI623528B TW I623528 B TWI623528 B TW I623528B TW 105144241 A TW105144241 A TW 105144241A TW 105144241 A TW105144241 A TW 105144241A TW I623528 B TWI623528 B TW I623528B
Authority
TW
Taiwan
Prior art keywords
phenyl
pyridin
difluoro
piperazin
hydroxy
Prior art date
Application number
TW105144241A
Other languages
English (en)
Chinese (zh)
Other versions
TW201734000A (zh
Inventor
克里斯多夫Ｍ 耶茨
聖米Ｒ 雪佛
威廉Ｊ 荷科斯特
Original Assignee
維愛美製藥公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 維愛美製藥公司 filed Critical 維愛美製藥公司
Publication of TW201734000A publication Critical patent/TW201734000A/zh
Application granted granted Critical
Publication of TWI623528B publication Critical patent/TWI623528B/zh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6558—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system
    • C07F9/65583—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system each of the hetero rings containing nitrogen as ring hetero atom

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Biochemistry (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Pyridine Compounds (AREA)
TW105144241A 2015-12-30 2016-12-30 金屬酶抑制劑化合物、抑制金屬酶活性之方法、組合物、治療或預防植物疾病或病症之方法及其用途 TWI623528B (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562273167P 2015-12-30 2015-12-30
US62/273,167 2015-12-30

Publications (2)

Publication Number Publication Date
TW201734000A TW201734000A (zh) 2017-10-01
TWI623528B true TWI623528B (zh) 2018-05-11

Family

ID=59225927

Family Applications (1)

Application Number Title Priority Date Filing Date
TW105144241A TWI623528B (zh) 2015-12-30 2016-12-30 金屬酶抑制劑化合物、抑制金屬酶活性之方法、組合物、治療或預防植物疾病或病症之方法及其用途

Country Status (12)

Country Link
US (1) US10464922B2 (https=)
EP (1) EP3397629B1 (https=)
JP (1) JP6803923B2 (https=)
KR (1) KR102240920B1 (https=)
CN (1) CN108779094B (https=)
AU (1) AU2016380349B2 (https=)
BR (1) BR112018013522A2 (https=)
CA (1) CA3006469C (https=)
EA (1) EA038421B1 (https=)
MX (1) MX376201B (https=)
TW (1) TWI623528B (https=)
WO (1) WO2017117393A1 (https=)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2015231226B2 (en) 2014-03-19 2019-04-04 Mycovia Pharmaceuticals, Inc. Antifungal compound process
JP6572234B2 (ja) 2014-03-19 2019-09-04 ヴィアメット ファーマスーティカルズ（エヌシー），インコーポレイテッド 抗真菌化合物の調製方法
CA2942936A1 (en) 2014-03-19 2015-09-24 Viamet Pharmaceuticals, Inc. Antifungal compound process
BR112016021257B1 (pt) 2014-03-19 2021-03-02 Viamet Pharmaceuticals (NC), Inc. 2-(2,4- difluorofenil-1,1-diflúor-1-(5-substituído-piridin-2-il)-3- (1h-tetrazol-1-il)propan-2-óis e processos para preparação e uso dos mesmos
ES2800905T3 (es) 2014-03-19 2021-01-05 Mycovia Pharmaceuticals Inc Procedimiento para compuesto antifúngico
CA2942972A1 (en) 2014-03-19 2015-09-24 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Antifungal compound process
JP6633539B2 (ja) 2014-03-19 2020-01-22 ダウ アグロサイエンシィズ エルエルシー ２−（２，４−ジフルオロフェニル）−１，１−ジフルオロ−１−（５−置換−ピリジン−２−イル）−３−（１ｈ−テトラゾール−１−イル）プロパン−２−オールおよびその調製工程
CA2942231A1 (en) 2014-03-19 2015-09-24 Viamet Pharmaceuticals, Inc. Antifungal compound process
AU2015231275B2 (en) 2014-03-19 2019-03-07 Mycovia Pharmaceuticals, Inc. Antifungal compound process
JP6847458B2 (ja) 2015-09-18 2021-03-24 マイコヴィア ファーマシューティカルズ，インコーポレイテッド 抗真菌化合物のプロセス
WO2019182743A1 (en) * 2018-03-20 2019-09-26 Innocrin Pharmaceuticals, Inc. Compositions for the treatment of brain tumors
US12357615B2 (en) 2018-10-11 2025-07-15 Kembi Therapeutics Pty Ltd Compositions for the treatment of brain tumors
JP2024513227A (ja) 2021-04-05 2024-03-22 ハリア・セラピューティクス・インコーポレイテッド Ｎｅｋ７阻害剤
CN113444131B (zh) * 2021-06-24 2022-10-21 鲁东大学 N-乙酰氨基葡萄糖类化合物及其制备方法和应用
WO2023069613A1 (en) * 2021-10-20 2023-04-27 Ohio State Innovation Foundation Arylimidamides for use in treatment of cancers
CN115466227B (zh) * 2022-06-30 2024-07-19 杭州国瑞生物科技有限公司 一种3-(氯甲基)-1-甲基-1h-1,2,4-三唑盐酸盐的制备方法

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015143137A1 (en) * 2014-03-19 2015-09-24 Viamet Pharmaceuticals, Inc. Antifungal compound process

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4921475A (en) 1983-08-18 1990-05-01 Drug Delivery Systems Inc. Transdermal drug patch with microtubes
US5087240A (en) 1983-08-18 1992-02-11 Drug Delivery Systems Inc. Transdermal drug patch with conductive fibers
US4738851A (en) 1985-09-27 1988-04-19 University Of Iowa Research Foundation, Inc. Controlled release ophthalmic gel formulation
US5163899A (en) 1987-03-20 1992-11-17 Drug Delivery Systems Inc. Transdermal drug delivery system
US5312325A (en) 1987-05-28 1994-05-17 Drug Delivery Systems Inc Pulsating transdermal drug delivery system
GB8804164D0 (en) 1988-02-23 1988-03-23 Tucker J M Bandage for administering physiologically active compound
US4882150A (en) 1988-06-03 1989-11-21 Kaufman Herbert E Drug delivery system
US5008110A (en) 1988-11-10 1991-04-16 The Procter & Gamble Company Storage-stable transdermal patch
US5088977A (en) 1988-12-21 1992-02-18 Drug Delivery Systems Inc. Electrical transdermal drug applicator with counteractor and method of drug delivery
US5521222A (en) 1989-09-28 1996-05-28 Alcon Laboratories, Inc. Topical ophthalmic pharmaceutical vehicles
EP0431519B1 (en) 1989-12-04 1994-06-15 G.D. Searle & Co. System for transdermal albuterol administration
US5077033A (en) 1990-08-07 1991-12-31 Mediventures Inc. Ophthalmic drug delivery with thermo-irreversible gels of polxoxyalkylene polymer and ionic polysaccharide
ATE141502T1 (de) 1991-01-15 1996-09-15 Alcon Lab Inc Verwendung von karrageenan in topischen ophthalmologischen zusammensetzungen
US5352456A (en) 1991-10-10 1994-10-04 Cygnus Therapeutic Systems Device for administering drug transdermally which provides an initial pulse of drug
DE69228827T2 (de) 1991-12-18 1999-10-21 Minnesota Mining And Mfg. Co., Saint Paul Mehrschichtige sperrstrukturen
EP0553769B1 (de) 1992-01-29 1996-01-03 FRANZ VÖLKL GmbH & CO. SKI UND TENNIS SPORTARTIKELFABRIK KG Ballspielschläger, insbesondere Tennisschläger
ES2199251T3 (es) * 1994-06-15 2004-02-16 Otsuka Pharmaceutical Company, Limited Derivados benzoheterociclicos utilizables como moduladores de vasopresina o de oxitocina.
IL114193A (en) 1994-06-20 2000-02-29 Teva Pharma Ophthalmic pharmaceutical compositions based on sodium alginate
ES2094688B1 (es) 1994-08-08 1997-08-01 Cusi Lab Manoemulsion del tipo de aceite en agua, util como vehiculo oftalmico y procedimiento para su preparacion.
IT1283911B1 (it) 1996-02-05 1998-05-07 Farmigea Spa Soluzioni oftalmiche viscosizzate con polisaccaridi della gomma di tamarindo
US5800807A (en) 1997-01-29 1998-09-01 Bausch & Lomb Incorporated Ophthalmic compositions including glycerin and propylene glycol
US6261547B1 (en) 1998-04-07 2001-07-17 Alcon Manufacturing, Ltd. Gelling ophthalmic compositions containing xanthan gum
US6197934B1 (en) 1998-05-22 2001-03-06 Collagenesis, Inc. Compound delivery using rapidly dissolving collagen film
AUPP999799A0 (en) * 1999-04-27 1999-05-20 Fujisawa Pharmaceutical Co., Ltd. New compound
EP1372394A1 (en) * 2001-04-03 2004-01-02 Schering Corporation Antifungal composition with enhanced bioavailability
AU2011242562B2 (en) * 2010-04-24 2016-10-13 Mycovia Pharmaceuticals, Inc. Metalloenzyme inhibitor compounds
KR20140093610A (ko) * 2011-04-21 2014-07-28 재단법인 한국파스퇴르연구소 소염 화합물
AU2013209520A1 (en) * 2012-01-20 2014-08-28 Viamet Pharmaceuticals (NC), Inc. Metalloenzyme inhibitor compounds
ES2774267T3 (es) * 2012-01-20 2020-07-20 Mycovia Pharmaceuticals Inc Compuestos inhibidores de metaloenzimas
US9688671B2 (en) * 2013-06-12 2017-06-27 Viamet Pharmaceuticals, Inc. Metalloenzyme inhibitor compounds

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015143137A1 (en) * 2014-03-19 2015-09-24 Viamet Pharmaceuticals, Inc. Antifungal compound process

Also Published As

Publication number Publication date
EP3397629A4 (en) 2019-06-05
AU2016380349B2 (en) 2020-10-29
EP3397629A1 (en) 2018-11-07
JP6803923B2 (ja) 2020-12-23
TW201734000A (zh) 2017-10-01
AU2016380349A1 (en) 2018-06-14
EA201891539A1 (ru) 2018-12-28
KR102240920B1 (ko) 2021-04-16
EP3397629B1 (en) 2023-04-19
BR112018013522A2 (pt) 2018-12-11
WO2017117393A1 (en) 2017-07-06
US20190016700A1 (en) 2019-01-17
MX376201B (es) 2025-03-07
CN108779094B (zh) 2021-11-16
CA3006469C (en) 2023-01-10
JP2019502755A (ja) 2019-01-31
CN108779094A (zh) 2018-11-09
US10464922B2 (en) 2019-11-05
MX2018008105A (es) 2018-11-12
CA3006469A1 (en) 2017-07-06
EA038421B1 (ru) 2021-08-26
KR20180099845A (ko) 2018-09-05

Similar Documents

Publication Publication Date Title
TWI623528B (zh) 金屬酶抑制劑化合物、抑制金屬酶活性之方法、組合物、治療或預防植物疾病或病症之方法及其用途
CN104203936B (zh) 金属酶抑制剂化合物
KR102061137B1 (ko) 금속효소 억제제 화합물
KR101379370B1 (ko) 금속효소 억제제 화합물
AU2014209107B2 (en) Metalloenzyme inhibitor compounds
JP6386035B2 (ja) 金属酵素阻害剤化合物
EP3119745A1 (en) Antifungal compound process
EP3066098A1 (de) Substituierte uracile und ihre verwendung
HK1202872B (en) Metalloenzyme inhibitor compounds
HK1224663A1 (zh) 取代的尿嘧啶及其用途

Legal Events

Date Code Title Description
MM4A Annulment or lapse of patent due to non-payment of fees